Clinical Report: Eligibility for Testosterone Hormone Therapy in the United States

Background

Testosterone replacement therapy (TRT) eligibility criteria remain stringent. Understanding these criteria is crucial for healthcare providers to ensure appropriate treatment for men with testosterone deficiency.

Data Highlights

No numerical data available in the source material.

Key Findings

• Eligibility for TRT requires both compatible symptoms and consistently low testosterone levels on two separate assays.
• A commonly used diagnostic cut point for total testosterone is <300 ng/dL.
• Routine population screening for testosterone deficiency is not advised.
• Contraindications for TRT include known prostate or breast cancer, untreated severe obstructive sleep apnea, and uncontrolled heart failure.
• Recent FDA updates have removed boxed warnings about increased cardiovascular events but retained warnings about blood pressure increases.

Clinical Implications

Healthcare providers should adhere to established guidelines when diagnosing and prescribing TRT, including awareness of contraindications and recent regulatory changes.

Conclusion

The eligibility criteria for testosterone therapy in the U.S. are designed to ensure appropriate treatment for men with testosterone deficiency.

Related Resources & Content

1. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline, The Journal of Clinical Endocrinology & Metabolism, 2018 -- Guidelines on testosterone therapy eligibility.
2. FDA Signals New Testosterone Pathway, Conexiant, 2025 -- Updates on testosterone therapy indications.
3. HHS Announces Requested Updates to Testosterone Therapy Product Labels, U.S. Department of Health and Human Services, 2025 -- Changes to testosterone therapy labeling.
4. The Journal of Clinical Endocrinology & Metabolism — Impact of Testosterone Therapy on Male Sexual Function: A Secondary Analysis from the T4DM Trial
5. the asco post — Risk of Gynecologic Cancers After 5 Years of Testosterone Use
6. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society* Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic
7. FDA issues class-wide labeling changes for testosterone products | FDA
8. Cardiovascular Safety of Testosterone-Replacement Therapy | New England Journal of Medicine
9. Testosterone Treatment and Fractures in Men with Hypogonadism | New England Journal of Medicine
10. Cardiovascular safety of testosterone replacement therapy in men: an updated systematic review and meta-analysis - PubMed
11. Full article: Standards of Care for the Health of Transgender and Gender Diverse People, Version 8